Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Opportunities to Optimize Cancer Policies Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




May
11
Today In Oncology
Meta-Analysis Explores Impact of Ovarian Function Suppression on Breast Cancer Recurrence and Survival
B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic GVHD
FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma
ASCO Certifies First Virtual Cancer Clinic
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo